Chardan Capital Reaffirms Buy Rating for Cognition Therapeutics (NASDAQ:CGTX)

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reissued by research analysts at Chardan Capital in a report issued on Friday,Benzinga reports. They presently have a $11.00 price objective on the stock.

A number of other equities analysts also recently commented on the company. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Cognition Therapeutics in a research note on Monday, November 4th. B. Riley reaffirmed a “neutral” rating and issued a $1.00 target price (down from $5.00) on shares of Cognition Therapeutics in a research report on Tuesday, August 6th. Finally, Cantor Fitzgerald downgraded shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, July 30th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Cognition Therapeutics Stock Performance

Cognition Therapeutics stock opened at $0.46 on Friday. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The firm’s 50-day moving average is $0.50 and its 200-day moving average is $1.20. The company has a market cap of $18.51 million, a P/E ratio of -0.48 and a beta of 1.34.

Institutional Trading of Cognition Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sigma Planning Corp increased its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the period. Mercer Global Advisors Inc. ADV grew its holdings in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after acquiring an additional 24,050 shares during the period. CM Management LLC grew its holdings in Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after acquiring an additional 25,000 shares during the period. Bangor Savings Bank raised its position in Cognition Therapeutics by 41.6% in the second quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Levin Capital Strategies L.P. acquired a new stake in Cognition Therapeutics in the 1st quarter valued at about $55,000. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.